Back

Differential effects of sodium-glucose cotransporter 2 inhibitors and sacubitril-valsartan in incidence of heart failure with improved ejection fraction

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in chronic heart failure - heart failure with HFrEF (3) Heart Failure with Reduced Ejection Fraction (HFrEF) Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Mr Mauro Moreira

Hospital Centre do Tamega e Sousa, Penafiel (Portugal)

5 More presentations in this session

Presentation thumbnail
Long term outcomes with sacubitril valsartan in HFrEF: insights from a real world cohort.
Doctor S. Martinez Gutierrez (Las Palmas de Gran Canaria, ES)
Abstract Slides
Presentation thumbnail
Predictors of heart failure with improved ejection fraction: a real world analysis
Mr M. Moreira (Penafiel, PT)
Abstract Slides
Presentation thumbnail
Persistent racial and gender disparities in heart transplantation rates despite adjustment for sensitization and medical urgency in the modern allocation era
Doctor K. Dulnuan (Staten Island, US)
Abstract Slides
Presentation thumbnail
Redefining the threshold: pre-transplant pulmonary vascular resistance and post-transplant survival in the HeartMate 3 era
Doctor K. Dulnuan (Staten Island, US)
Abstract Slides
Presentation thumbnail
The best combination of mechanical circulatory support used in critical stage of heart failure in the six years retrospective analysis.
Associate Professor A. Konopka (Warsaw, PL)
Abstract Slides

Access the full session

Session thumbnail
ePosters in chronic heart failure - heart failure with HFrEF (3)

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Congress Session
Meet the Experts: summation of the science - treatment of chronic heart failure in 2023

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources